November 17, 2026
Meetings / Conferences SOHO 2026 MDS News Myelodysplastic Syndromes Video Interviews

What are the challenges of predicting durable CR in HR-MDS?

Julie Braish, MD, a fellow at Moffitt Cancer Center, discusses a retrospective study to determine if durable complete remission, defined as lasting at least six months, could be predicted using baseline clinical and molecular characteristics in patients with higher-risk myelodysplastic syndromes. The data were presented in a poster at the SOHO 2026 Annual Meeting in Houston, Texas.

Dr. Braish and her team analyzed why these traditional baseline clinical and molecular characteristics, including genetic mutations and prognostic scoring systems such as IPSS-R, have limited ability to predict which patients will achieve lasting remission following standard-of-care hypomethylating agent therapy.

The investigators reported that durable CR and baseline characteristics do not necessarily indicate how patients will respond to therapy.

“Durable CR might reflect treatment-responsive disease biology not fully captured by baseline pretreatment features, thus supporting future investigation of early treatment-response dynamics and adaptive biomarkers,” Dr. Braish and investigators wrote in the SOHO 2026 poster abstract.

 

Reference

Braish J. Abstract MDS-515. Durable Complete Remission Following HMA Therapy in Higher-Risk MDS Is Not Fully Determined by Baseline Disease Biology. SOHO 2026. Houston, Texas.

Leave feedback about this

  • Quality
  • Price
  • Service

PROS

+
Add Field

CONS

+
Add Field